Skip to main content
AMCP 2025 Main banner
Back

Keynote

(K2) GLP-1’s for Everything! The gift that keeps on giving… A review of the body of evidence and implications for managed care

Thursday, April 3, 2025
8:30 AM – 9:45 AM CST
ACPE UAN: | Contact Hours: 1.25 | Activity Type: Knowledge-based
Disclosure(s):
Angela Allerman, PharmD, BCPS: No financial relationships to disclose
Amy Lugo, PharmD, BCPS, BC-ADM: No financial relationships to disclose
Kristen Patti, PharmD, MS: No financial relationships to disclose
You get a GLP-1! You get a GLP-1! Everyone gets a GLP-1 ! This session delves into the transformative potential of GLP-1 receptor agonists (GLP-1RAs) across a wide range of conditions, including obstructive sleep apnea, binge eating disorder, substance use disorder, NASH, heart failure, osteoarthritis, cystic fibrosis, PCOS, and neurocognitive disorders like Parkinson’s and Alzheimer’s dementia. Attendees will gain insights into the latest advancements in the GLP-1RA pipeline and explore emerging therapies and their potential to reshape treatment paradigms.

Additionally, this discussion will address key implications for managed care and highlight the challenges in formulary management and benefit design. Join us for an in-depth exploration of these innovative therapies and their potential to revolutionize care across diverse health conditions.

Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Summarize the therapeutic areas where GLP-1Ras are being studied and evaluate the evidence.
  2. Discuss challenges related to the GLP-1RA indications and implications for managed care in formulary management and utilization management.
  3. Review the GLP-1RA/GIP/GCGR pipeline.